カテゴリ： Bahamas, GlobalData, 企業調査

Nymox Pharmaceutical Corp (NYMX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Nymox Pharmaceutical Corp (NYMX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10056
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：75
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：Bahamas
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Nymox Pharmaceutical Corp (Nymox) is a biopharmaceutical company that undertakes the research and development of therapeutics and diagnostics devices to target the unmet needs of the aging population. The company markets diagnostic products for measuring tobacco product exposure and for the diagnosis of Alzheimer’s disease. Its diagnostic product portfolio includes NicAlert test to determine smoking status; and TobacAlert home test to determine person’s level of exposure to tobacco products, including second hand smoke. Nymox’s lead drug candidate, NX-1207 intended for the treatment of BPH (benign prostatic hyperplasia) and certain types of cancer. It has subsidiaries in New Jersey, the US. Nymox is headquartered in Nassau, the Bahamas.

Nymox Pharmaceutical Corp (NYMX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Nymox Pharmaceutical Corp, Medical Devices Deals, 2012 to YTD 2018 11
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deal Details 15
Equity Offering 15
Nymox Pharma Raises USD16.3 Million in Private Placement of Shares 15
Nymox Pharma Raises USD3 Million in Private Placement of Shares 16
Nymox Pharma Raises USD2.24 Million in Private Placement of Shares 17
Nymox Pharma Raises Additional USD2.1 Million in Private Placement of Shares 18
Nymox Pharmaceutical to Raise USD12 Million in Private Placement 19
Nymox Pharma Raises USD0.8 Million in Private Placement of Shares 20
Nymox Pharma Raises USD0.35 Million in Private Placement of Shares 21
Nymox Pharma Raises USD0.59 Million in Private Placement of Shares 22
Nymox Pharma Raises USD0.4 Million in Private Placement of Shares 23
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 24
Nymox Pharma Raises USD0.25 Million in Private Placement of Shares 25
Nymox Pharma Raises USD0.15 Million in Private Placement of Shares 26
Nymox Pharma Raises USD0.15 million in Private Placement of Shares 27
Nymox Pharma Raises USD0.15 Million in Private Placement of Shares 28
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 29
Nymox Pharma Raises USD0.3 million in Private Placement of Shares 30
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 31
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 32
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 33
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 34
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 35
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 36
Nymox Pharma Raises USD0.2 Million in Private Placement of Shares 37
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 38
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 39
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 40
Nymox Pharma Raises USD0.3 million in Private Placement of Shares 41
Nymox Pharma Raises USD0.14 Million in Private Placement of Shares 42
Nymox Pharma Raises USD0.15 Million in Public Offering of Shares 43
Nymox Pharma Raises USD0.35 Million in Public Offering of Shares 44
Nymox Pharma Raises USD0.35 Million in Private Placement of Shares 45
Nymox Pharma Raises USD0.35 Million in Private Placement of Shares 46
Nymox Pharma Raises USD0.4 Million in Private Placement of Shares 47
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 48
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 49
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 50
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 51
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 52
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 53
Nymox Pharma Raises USD0.4 Million in Private Placement of Shares 54
Nymox Pharma Raises USD0.5 Million in Private Placement of Shares 55
Nymox Pharma Raises USD0.2 Million in Private Placement of Shares 56
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 57
Nymox Pharma Raises USD0.2 Million in Private Placement of Shares 58
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 59
Nymox Pharma Raises USD0.4 Million in Private Placement of Shares 60
Nymox Pharma Raises USD0.2 Million in Private Placement of Shares 61
Nymox Pharma Raises USD1.1 Million in Private Placement of Shares 62
Nymox Pharma Raises USD1 Million in Private Placement of Shares 63
Nymox Pharma Completes Private Placement Of Shares For US$15 Million 64
Nymox Pharma Raises USD1 Million in Private Placement of Shares 65
Nymox Pharma Raises USD0.5 Million in Private Placement of Shares 66
Nymox Pharma Raises USD0.5 Million in Private Placement of Shares 67
Nymox Pharma Raises USD0.5 Million in Private Placement of Shares 68
Nymox Pharma Raises USD1 Million in Private Placement of Shares 69
Debt Offering 70
Nymox Pharma Raises USD1.1 Million in Public Offering of Debenture 70
Nymox Pharmaceutical Corp – Key Competitors 71
Nymox Pharmaceutical Corp – Key Employees 72
Nymox Pharmaceutical Corp – Locations And Subsidiaries 73
Head Office 73
Other Locations & Subsidiaries 73
Recent Developments 74
Other Significant Developments 74
Jul 02, 2018: NYMOX Announces Expanded Marketing Plans 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75

List of Tables
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Nymox Pharmaceutical Corp, Deals By Therapy Area, 2012 to YTD 2018 10
Nymox Pharmaceutical Corp, Medical Devices Deals, 2012 to YTD 2018 11
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Nymox Pharma Raises USD16.3 Million in Private Placement of Shares 15
Nymox Pharma Raises USD3 Million in Private Placement of Shares 16
Nymox Pharma Raises USD2.24 Million in Private Placement of Shares 17
Nymox Pharma Raises Additional USD2.1 Million in Private Placement of Shares 18
Nymox Pharmaceutical to Raise USD12 Million in Private Placement 19
Nymox Pharma Raises USD0.8 Million in Private Placement of Shares 20
Nymox Pharma Raises USD0.35 Million in Private Placement of Shares 21
Nymox Pharma Raises USD0.59 Million in Private Placement of Shares 22
Nymox Pharma Raises USD0.4 Million in Private Placement of Shares 23
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 24
Nymox Pharma Raises USD0.25 Million in Private Placement of Shares 25
Nymox Pharma Raises USD0.15 Million in Private Placement of Shares 26
Nymox Pharma Raises USD0.15 million in Private Placement of Shares 27
Nymox Pharma Raises USD0.15 Million in Private Placement of Shares 28
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 29
Nymox Pharma Raises USD0.3 million in Private Placement of Shares 30
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 31
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 32
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 33
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 34
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 35
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 36
Nymox Pharma Raises USD0.2 Million in Private Placement of Shares 37
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 38
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 39
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 40
Nymox Pharma Raises USD0.3 million in Private Placement of Shares 41
Nymox Pharma Raises USD0.14 Million in Private Placement of Shares 42
Nymox Pharma Raises USD0.15 Million in Public Offering of Shares 43
Nymox Pharma Raises USD0.35 Million in Public Offering of Shares 44
Nymox Pharma Raises USD0.35 Million in Private Placement of Shares 45
Nymox Pharma Raises USD0.35 Million in Private Placement of Shares 46
Nymox Pharma Raises USD0.4 Million in Private Placement of Shares 47
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 48
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 49
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 50
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 51
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 52
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 53
Nymox Pharma Raises USD0.4 Million in Private Placement of Shares 54
Nymox Pharma Raises USD0.5 Million in Private Placement of Shares 55
Nymox Pharma Raises USD0.2 Million in Private Placement of Shares 56
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 57
Nymox Pharma Raises USD0.2 Million in Private Placement of Shares 58
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 59
Nymox Pharma Raises USD0.4 Million in Private Placement of Shares 60
Nymox Pharma Raises USD0.2 Million in Private Placement of Shares 61
Nymox Pharma Raises USD1.1 Million in Private Placement of Shares 62
Nymox Pharma Raises USD1 Million in Private Placement of Shares 63
Nymox Pharma Completes Private Placement Of Shares For US$15 Million 64
Nymox Pharma Raises USD1 Million in Private Placement of Shares 65
Nymox Pharma Raises USD0.5 Million in Private Placement of Shares 66
Nymox Pharma Raises USD0.5 Million in Private Placement of Shares 67
Nymox Pharma Raises USD0.5 Million in Private Placement of Shares 68
Nymox Pharma Raises USD1 Million in Private Placement of Shares 69
Nymox Pharma Raises USD1.1 Million in Public Offering of Debenture 70
Nymox Pharmaceutical Corp, Key Competitors 71
Nymox Pharmaceutical Corp, Key Employees 72
Nymox Pharmaceutical Corp, Subsidiaries 73

List of Figures
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Nymox Pharmaceutical Corp, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Nymox Pharmaceutical Corp (NYMX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Boise Cascade Company：企業の戦略・SWOT・財務情報
    Boise Cascade Company - Strategy, SWOT and Corporate Finance Report Summary Boise Cascade Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Primeline Energy Holdings Inc (PEH)：企業の財務・戦略的SWOT分析
    Summary Primeline Energy Holdings Inc (Primeline Energy) is an upstream company that explores oil and gas. The company acquires and explores crude oil and natural gas properties across China. It owns and operates exploration and development rights in two offshore blocks in the East China Sea. Primel …
  • University of Tokyo-製薬・医療分野：企業M&A・提携分析
    Summary The University of Tokyo (UTokyo) is a research university that offers undergraduate, graduate, professional and distance learning programs. The university offers courses in the field of science, agriculture, economics, law, medicine, engineering, pharmaceutical sciences, and others. It also …
  • Saudi Arabian Mining Co：戦略・SWOT・企業財務分析
    Saudi Arabian Mining Co - Strategy, SWOT and Corporate Finance Report Summary Saudi Arabian Mining Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Phillips-Medisize LLC：企業の戦略的SWOT分析
    Phillips-Medisize LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • BioElectron Technology Corp-製薬・医療分野：企業M&A・提携分析
    Summary BioElectron Technology Corp(BioElectron) formerly known as Edison Pharmaceuticals Inc, discovers and develops shared (redox) disease drugs. The company’s pipeline products comprise EPI-743, a drug candidate for inherited mitochondrial diseases and EPI-589 drug candidate entering phase 1 clin …
  • WuXi NextCODE Genomics：製薬・医療：M&Aディール及び事業提携情報
    Summary WuXi NextCODE Genomics USA Inc (WuXi NextCODE), a subsidiary of Wuxi Pharmatech (Cayman) Inc, is a genomic information company that offers competencies in generating, organizing, mining, sharing and applying genomic data. The company develops gene sequence analysis platform and database arch …
  • Magellan Health Inc (MGLN)：製薬・医療：M&Aディール及び事業提携情報
    Summary Magellan Health Inc (Magellan) is a health care management company which manages behavioral health, radiology and specialty pharmaceuticals, and public sector pharmacy benefits programs. The company provides behavioral healthcare, specialty solutions, and pharmacy management services and int …
  • Georgia Power Co (GPW)：電力：M&Aディール及び事業提携情報
    Summary Georgia Power Co (Georgia Power), a subsidiary of the Southern Power Company, generates, transmits, distributes and sells electricity. The company produces electricity using various sources of energy such as coal, nuclear, solar, gas and hydro. It supplies electricity in Georgia and to whole …
  • Neue Bank AG：企業の戦略・SWOT・財務情報
    Neue Bank AG - Strategy, SWOT and Corporate Finance Report Summary Neue Bank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Hargreaves Services Plc：企業の戦略・SWOT・財務分析
    Hargreaves Services Plc - Strategy, SWOT and Corporate Finance Report Summary Hargreaves Services Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • The Pack Corporation
    The Pack Corporation - Strategy, SWOT and Corporate Finance Report Summary The Pack Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Nissan Motor Co., Ltd.：企業の戦略・SWOT・財務情報
    Nissan Motor Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nissan Motor Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • YGM Trading Ltd.：企業の戦略・SWOT・財務情報
    YGM Trading Ltd. - Strategy, SWOT and Corporate Finance Report Summary YGM Trading Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Fubon Financial Holding Co Ltd：戦略・SWOT・企業財務分析
    Fubon Financial Holding Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Fubon Financial Holding Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Norwegian Energy Company ASA (NOR)：企業の財務・戦略的SWOT分析
    Summary Norwegian Energy Company ASA (Noreco) is an upstream oil and gas company which carries out exploration, production and recovery of hydrocarbon resources. The company focuses on the development of oil and gas reserves; reservoir management and drilling activities; and acquisition of Shell’s u …
  • Aiful Corp：企業の戦略・SWOT・財務分析
    Aiful Corp - Strategy, SWOT and Corporate Finance Report Summary Aiful Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Giordano International Limited (709)：企業の財務・戦略的SWOT分析
    Giordano International Limited (709) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Blackbird Energy Inc (BBI)：企業の財務・戦略的SWOT分析
    Summary Blackbird Energy Inc (Blackbird Energy), formerly Blackbird Investments Inc, is an independent oil and gas exploration and development company that acquires, explores, produces and develops oil and gas properties in Western Canada. The company holds interests in Elmworth Project which concen …
  • ComOps Limited (COM)：企業の財務・戦略的SWOT分析
    ComOps Limited (COM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆